Nitritex Donates Personal Protection Equipment in Response to Ebola Emergency Appeal
In response to the Ebola outbreak in West Africa, Nitritex has donated seven pallets of personal protection equipment (PPE), including disposable coveralls, aprons, and more than 200,000 gloves to protect the healthcare workers helping to save lives during this crisis.
In response to the Ebola outbreak in West Africa, Nitritex has donated seven pallets of personal protection equipment (PPE), including disposable coveralls, aprons, and more than 200,000 gloves to protect the healthcare workers helping to save lives during this crisis. The donation follows the Ebola emergency appeal issued by Scotia Aid-Sierra Leone, a charity set up in 2010 to improve the lives of the people of Sierra Leone through educational and social programes.
Nitritex Ltd manufactures a range of cleanroom consumables, marketed under the BioClean brand. Products include gloves, goggles, masks, garments and accessories designed for critical environments where product and process protection is paramount.
Source: Nitritex Ltd
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
